Allogene Therapeutics (ALLO) Non-Current Deferred Tax Liability (2018 - 2021)

Allogene Therapeutics has reported Non-Current Deferred Tax Liability for 3 years, with the latest figure at $68000.0 in Q4 2021.

• Quarterly Non-Current Deferred Tax Liability changed N/A year-over-year to $68000.0 in Q4 2021, while the trailing twelve-month figure through Dec 2021 was $68000.0 (changed N/A YoY) and the FY2021 annual result came in at $68000.0, changed N/A from the prior year.
• Non-Current Deferred Tax Liability retreated to $68000.0 in Q4 2021 per ALLO's latest filing, from $361000.0 in the prior quarter.
• Over five years, Non-Current Deferred Tax Liability peaked at $531000.0 in Q4 2018 and troughed at $68000.0 in Q4 2021.
• A 3-year average of $320000.0 and a median of $361000.0 in 2019 frame the typical range for Non-Current Deferred Tax Liability.
• The widest YoY moves for Non-Current Deferred Tax Liability: up 32.02% in 2019, down 32.02% in 2019.
• Over 3 years, Non-Current Deferred Tax Liability stood at $531000.0 in 2018, then plunged by 32.02% to $361000.0 in 2019, then slumped by 81.16% to $68000.0 in 2021.
• According to Business Quant data, Non-Current Deferred Tax Liability over the past three periods registered $68000.0, $361000.0, and $531000.0 for Q4 2021, Q4 2019, and Q4 2018 respectively.